Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Rizzuto, Ivana ^a   Behrens, Renee F ^b   Smith, Lesley A ^c  

^a PRINCESS ALEXANDRA HOSPITAL NHS TRUST   (United Kingdom)

^b BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^c OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; FERTILITY PROMOTING AGENT;

CANCER RISK; DRUG SAFETY; DRUG USE; FEMALE INFERTILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; FEMALE; OVARY TUMOR; OVULATION INDUCTION; PATHOLOGY; PROCEDURES; CHEMICALLY INDUCED DISORDER; METHODOLOGY;

CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; OVARIAN NEOPLASMS; OVULATION INDUCTION;

EID: 84893360081     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008215.pub2     Document Type: Review

References (172)

1. Brinton LA, Lamb E, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk after the use of ovulation stimulating drugs. Obstetrics and Gynecology 2004;103:1194-203.
2. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology 2008;169(3):365-75.
3. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility 2002;77(2):324-7.
4. Dos Santos Silva I, Wark PA, McCormack VA, Mayer D, Overton C, Little V, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. British Journal of Cancer 2009;100:1824-31.
5. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction 2002;17(8):2209-13.
6. Franceschini S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Human Reproduction 1994;9(9):1673-5.
7. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 2009;338:1-8.
8. Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren K-G, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Human Reproduction 2011;26(1):253-8.
9. Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, et al. Use of fertility drugs and risk of ovarian cancer: results from a US-based case-control study. Cancer Epidemiology, Biomarkers and Prevention 2012;21(8):1282-92.
10. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. International Journal of Gynecological Cancer 2003;13:23-7.
11. Lerner-Geva L, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecological Endocrinology 2012;28(10):809-14.
12. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology 1998;147:1038-42.
13. Mosgaard BJ, Lidegaard BJ, Kjaer SK, Schou G, Anderson AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertility and Sterility 1997;67(6):1005-12.
14. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Anderson AN. Ovarian stimulation and borderline ovarian tumours: a case-control study. Fertility and Sterility 1998;70(6):1049-55.
15. Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschini S, Crosignani PG. Treatment for infertility and risk of invasive epithelial ovarian cancer. Human Reproduction 1997;12(10):2159-61.
16. Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, et al. Treatment for fertility and risk of ovarian tumours of borderline malignancy. Human Reproduction 1998;68:226-8.
17. Parazzini F, Pelucchi C, Negri E, Franceschini S, Talamini R, Montella M, et al. Use of fertility drugs and risk of ovarian cancer. Human Reproduction 2001;16(7):1372-5.
18. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertility and Sterility 1999;71(5):853-9.
19. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumours in a cohort of infertile women. New England Journal of Medicine 1994;331(12):771-6.
20. Rossing MA, Tang Mei-Tzu C, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. American Journal of Epidemiology 2004;160(11):1070-8.
21. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, et al. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertility and Sterility 2009;91:1152-8.
22. Shushan A, Paltiel O, Isovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertility and Sterility 1996;65(1):13-8.
23. Van Leeuwen FE, Klip H, Mooij TM, Van de Swaluw AMG, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Human Reproduction 2011;26(12):3456-65.
24. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of infertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-90.
25. Yli-Kuha A-N, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction 2012;27(4):1149-55.
26. Adami H-O, Hsieh C-C, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-4.
27. Adelson MD, Reece MT. Effects of gonadotropin-realising hormone analogues on ovarian epithelial tumours. Clinical Obstetrics & Gynaecology 1993;36(3):690-700.
28. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes and Control 1996;7(4):421-7.
29. Al-Shawaf T, Zosmer A, Dirnfeld M, Grudzinskas G. Safety of drugs used in assisted reproduction techniques. Drug Safety 2005;28(6):513-28.
30. Althuis MD, Moghissi KS, WesthoffCL, Scoccia B, Lamb EJ, Lubin JH, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology 2005;161(7):607-15.
31. Anderson SM, Dimitrievich E. Ovulation induction for infertility is it safe or not?. South Dakota Journal of Medicine 1996;49(11):419-21.
32. Artini PG, Fasciani A, Cela V, Battaglia C, De Micheroux AA, D'Ambrogio G, et al. Fertility drugs and ovarian cancer. Gynecological Endocrinology 1997;11(1):59-68.
33. Attia A. EBM in action: Does ovulation induction increase the risk of ovarian cancer?. Middle East Fertility Society Journal 2006;11(2):135-9.
34. Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynaecologic cancers, breast cancer, and childhood cancers. Acta Obstetricia et Gynecologica Scandinavica 2004;83:1104-11.
35. Badawy A, Abdel Aal I, Abulatta M. Clomiphene or anastrozole for ovulation for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial. Fertility and Sterility 2009;92:860-3.
36. Balasch J, Penarrubia J, Marquez M, Mirkin SR, Carmona F, Barri PN, et al. Ovulation side and ovarian cancer. Gynecological Endocrinology Journal 1994;8(1):51-4.
37. Bandera C. Advances in the understanding of risk factors for ovarian cancer. Journal of Reproductive Medicine 2005;50:399-406.
38. Bayar U, Demirtas E, Usubütün A, Basaran M, Esinler I, Yarali H. Ovarian adenomyoma following gonadotrophin treatment for infertility. Reproductive Biomedicine Online 2006;13(5):676-9.
39. Bose CK. Clomiphene may not cause neoplasia in the ovary: an animal study on ovarian morphology, biochemistry and histochemistry. Journal Turkish-German Gynecological Association 2008;9(3):158-63.
40. Brekelmans CTM. Risk factors and risk reduction of breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology 2003;15:63-8.
41. Brinton LA. Hormones and risk of cancers of the breast and ovary. Cancer Causes Control 1996;7(6):569-71.
42. Brinton LA, Gridley G, Persson I, Baron J, Berqqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. American Journal of Obstetrics and Gynecology 1997;176:572-9.
43. Brinton L. Long-term effects of ovulation-stimulating drugs on cancer risk. Reproductive Biomedicine Online 2007;15(1):38-44.
44. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynaecologic cancers. Seminars in Reproductive Medicine 2012;30:131-45.
45. Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Current Opinion in Obstetrics and Gynaecology 1996;8:32-7.
46. Bristow RE, Karlan B. Ovulation induction, infertility, and ovarian cancer risk. Fertility and Sterility 1996;66(4):499-507.
47. Burger CW, Klip H, Van Leeuwen FE. In vitro fertilization, ovulation induction and the risk of cancer. CME Journal of Gynaecologic Oncology 2004;9:256-63.
48. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor - a review. Placenta 2008;29:169-77.
49. Chene G, Penault-Llorca F, Le Bouedec G, Mishellany F, Dauplat MM, Jaffeux P. Ovarian epithelial dysplasia after ovulation induction: time and dose effects. Human Reproduction 2009;24(1):132-8.
50. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Critical Reviews in Oncology Hematology 1997;25(1):1-9.
51. Cohen J. Fertility drugs and ovarian cancer. Fertility and Sterility 1993;60(3):406-8.
52. Cramer DW, Harlow BL, Titus-ErnstoffL, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998;351:104-7.
53. Crosbie E, Menon U. Epithelial ovarian cancer and induction of ovulation. Reviews in Gynaecological Practice 2005;5:131-8.
54. Croughan-Minihane M, Camarano L, Feigenbaum S, Adamson NGD, Cadieux M. The risk of ovarian cancer associated with infertility and infertility treatments. Fertility and Sterility 2001;76:S68.
55. Cusido M, Fabregas R, Pere Barris S, Escayola C, Nolsac Barr P. Ovulation induction treatment and risk of borderline ovarian tumours. Gynaecological Endocrinology 2007;23(7):373-6.
56. Demirol NA, Guven S, Gurgan T. Ovulation induction agents and cancer. Journal of the Turkish German Gynecological Association 2006;7(2):139-45.
57. Devesa M, Barri PN, Coroleu B. Assisted reproductive technology and ovarian cancer. Minerva Endocrinologica 2010;35(4):247-57.
58. Dos Santos Silva J, Maclean AB, Mayer D, Hardiman PJ, Lieberman G, Nieto JJ, et al. Does ovarian stimulation increase the risk of ovarian cancer?. Reproductive Medicine Review 2002;11(1):57-66.
59. Duckitt K, Templeton A. Cancer in women with infertility. Current Opinion of Obstetrics and Gynaecology 1998;10(3):199-03.
60. Duska L, Wallach EE. Infertility, ovulation induction, and epithelial ovarian cancer. Postgraduate Obstetrics & Gynaecology 1996;16:1-6.
61. Franceschini S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. International Journal of Cancer 1991;49:57-60.
62. Franco C, Coppola S, Prosperi Porta R, Patella A. Ovulation induction and risk of ovarian cancer [Induzione dell'ovulazione e rischio di neoplasie ovariche]. Minerva Ginecologica 2000;52:103-9.
63. Gaducci A, Gargini A, Palla E, Genazzani AR. Reproductive variables, fertility drugs and epithelial ovarian tumour risk. CME Journal of Gynaecologic Oncology 2004;9:245-52.
64. Gadducci A, Guerrieri ME, Genazzani AR. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynaecological Endocrinology 2013;29(1):30-5.
65. Genc G, Yilmaz N, Vygur D, Dogan M, Mollamahmutogli L. The effect of intrafollicular IGF 1 and IGFBP3 on IVF outcome in patients using different gonadotropins: a prospective study. Journal of Assisted Reproduction and Genetics 2011;28:405-10.
66. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiologic Reviews 1998;20(2):237-57.
67. Goldberg G, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link?. American Journal of Obstetrics and Gynecology 1992;166:853-4.
68. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiology Biomarkers and Prevention 2001;10:209-16.
69. Goshen R, Wessman A, Shoham Z. Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts. Baillieres Clinical Obstetrics and Gynaecology 1998;12(4):581-91.
70. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. Journal of Clinical Epidemiology 1990;43(6):559-68.
71. Hankinson S, Colditz G, Hunter DJ, Willett WC, Stampfer MJ, Rosner B. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284-90.
72. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumours of low malignant potential in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology 1992;136(10):1204-11.
73. He F, Gan X-L, Hu L-N. Ovulation induction and risk of ovarian cancer: a systematic review. Chinese Journal of Evidence-Based Medicine 2012;12(9):1129-34.
74. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
75. Horn-Ross P, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 1992;3:490-5.
76. Jensen A, Sharif H, Svare E, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiology of Biomarkers and Prevention 2007;16(7):1400-7.
77. Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50, 000 infertile Danish women. American Journal of Epidemiology 2008;168(1):49-57.
78. Kashyap S, Davis OK. Ovarian cancer and fertility medications: a critical appraisal. Seminars in Reproductive Medicine 2003;21(1):65-71.
79. Kaufman S, Spirtas R, Alexander NJ. Do fertility drugs cause ovarian tumours?. Journal of Women's Health 1995;4(3):247-59.
80. Kelly AM, Buckett WM, William M, Tan Seang L. Effect of repeated assisted reproductive technology on ovarian response. Current Opinion in Obstetrics and Gynecology 2003;15:219-24.
81. King TM. Ovarian cancer and fertility drugs. The Cancer Bulletin 1994;46(2):181-4.
82. Klip H, Burger CW, Kenemans P, Van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control 2000;11(4):319-44.
83. Klip H, Burger CW, de Kraker J, Van Leeuwen FE, OMEGA-project group. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Human Reproduction 2001;16(11):2451-8.
84. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57(2):45-8.
85. Kristiansson P, Bjor O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction 2007;22(2):421-6.
86. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynaecologic Oncology 2005;96:520-30.
87. Land JA. Ovulation, ovulation induction and ovarian carcinoma. Bailliere's Clinical Obstetrics and Gynaecology 1993;7(2):455-71.
88. La Vecchia C. Infertility, ovulation, induced ovulation and female cancers. European Journal of Cancer Prevention 2011;20(3):147-9.
89. Lerner-Geva L. The possible association between infertility, ovulation induction treatments and the incidence of cancer. CME Journal of Gynecologic Oncology 2004;9:236-44.
90. Lerner-Geva L, Keinan-Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, et al. Infertility, ovulation induction treatments and the incidence of breast cancer a historical prospective cohort of Israeli women. Breast Cancer Research and Treatment 2006;100:201-12.
91. Lerner-Geva L, Rabinovici J, Lunenfeld B. Ovarian stimulation: is there a long-term risk for ovarian, breast and endometrial cancer?. Women's Health (London England) 2010;6(6):831-9.
92. Li LL, Zhou J, Qian XJ, Chen YD. Meta-analysis on the possible association between in vitro fertilization and cancer risk. International Journal of Gynecological Cancer 2013;23:16-24.
93. Lopes P, Mensier A. Ovarian cancer and assisted reproductive technology. European Journal of Obstetrics and Gynecology and Reproductive Biology 1993;51:171-3.
94. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer - a short review on biological and clinical/epidemiological aspects. Molecular and Cellular Endocrinology 2007;269:61-4.
95. McGuire V, Felberg A, Mills M, Ostrow KL, Dicioccio R, John EM, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non carriers of BRCA 1 gene mutations. American Journal of Epidemiology 2004;160(7):613-8.
96. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. International Journal Cancer 2009;125(3):674-9.
97. Menon U, Gentry-Maraj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncology 2009;10(4):327-34.
98. Miao Q, Kong BH. A case-control study on etiology of epithelial ovarian cancer in Shandong Province. Al Zheng 2006;25(7):871-5.
99. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. American Journal of Epidemiology 2001;11:568-74.
100. Negri E, Franceschini S, Tzonou A, Booth M, La Vecchia C, Parazzini F, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. International Journal of Cancer 1991;49:50-6.
101. Ness RB, Grisso JA, Klapper J, Schlesselman J, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. American Journal of Epidemiology 2000;152(3):233-41.
102. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. American Journal of Epidemiology 2002;155:217-24.
103. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral oral contraceptives and tubal ligation, and risk of ovarian cancer. Annals of Epidemiology 2011;21:188-96.
104. Nieto JJ, Crow J, Sundaresan M, Constantinovici N, Perrett CW, MacLean AB, et al. Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecologic Oncology 2001;82:344-9.
105. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA 1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology 2010;28(2):240-4.
106. Ozcan Z, Celik H, Gurates B, Ozercan HI, Hanay F, Nalbant M, et al. Effects of ovulation induction agents on ovarian surface epithelial in rats. Reproductive Biomedicine Online 2009;19(3):314-8.
107. Ozdemir I, Ustundag N, Guven A, Duran B, Dermici F. Effect of clomiphene citrate on ovarian, endometrial, and cervical histologies in a rat model. Gynecologic and Obstetric Investigation 2005;60:181-5.
108. Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschini S, et al. Risk factors for different histological types of ovarian cancer. International Journal Gynecologic Cancer 2004;14:431-6.
109. Paulson RJ. Fertility drugs and ovarian epithelial cancer: is there a link?. Journal of Assisted Reproduction and Genetics 1996;13(10):751-6.
110. Persson I, Janson PO. Ovarian neoplasms. Protective or hazardous effects of sterilization, hysterectomy and hormonal infertility therapy?. Lakartidningen 1995;92(5):371-4.
111. Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. International Journal of Cancer 1995;62:678-84.
112. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clinical Endocrinology 1998;49:695-707.
113. Riman T, Dickman PW, Nilsson S, Correira N, Nordlinder H, Magnusson CM. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. American Journal of Epidemiology 2002;156(4):363-73.
114. Rish HA, Marrett LD, Jain M, Howe G. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. American Journal of Epidemiology 1996;144(4):363-72.
115. Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Health CW. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes and Control 1998;9:645-51.
116. Ron E, Lunenfeld B. A review of infertility and its treatment in the etiology of female reproductive and other cancers. Journal of Women's Health 1995;4(3):261-72.
117. Rosemberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL, Strom BL, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. American Journal of Epidemiology 1994;139(7):654-61.
118. Rosen B, Irvine J, Ritvo P, Shapiro H, Stewart D, Reynolds K, et al. The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk. Fertility and Sterility 1997;68(1):90-4.
119. Rosenblatt KA, Thomas DB and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lactation and the risk of epithelial ovarian cancer. International Journal of Epidemiology 1993;22(2):192-7.
120. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecologic Oncology 1996;60:3-7.
121. Schildkraut JM, Schwingl PJ, Bastos E, EvanoffA, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics and Gynecology 1996;88:554-9.
122. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today?. Fertility and Sterility 1994;62(3):433-48.
123. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer. A systematic review and metananalysis. Human Reproduction Update 2013;19(2):105-23.
124. Smith JA. The controversial association of the treatment of infertility with fertility agents and development of ovarian cancer: what should patients be told?. Oncology Spectrums 2001;2(6):428-31.
125. So W-K, Cheng J-C, Poon S-L, Leung PCK. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. The FEBS Journal 2008;275:5496-511.
126. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. Different risk factor profiles for mucinous and non mucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiology Biomarkers Prevention 2007;16(6):1160-6.
127. Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring?. Fertility and Sterility 1983;59(2):291-3.
128. Stein DE, Santoro N. Infertility, gonadotropins, and ovarian cancer. Controversies in Infertility Management 1997;8(2):289-303.
129. Tarlatzis BC, Grimbizis G, Bontis J, Mantalenakis S. Ovarian stimulation and ovarian tumours: a critical reappraisal. Human Reproduction Update 1995;1(3):284-301.
130. Trifonov I, Todorova M, Uzunova ZH. Stimulation of ovulation and ovarian cancer. Literature. Akush Ginekol (Sofiia) 2000;40(4):39-41.
131. Unkila-Kallio L, Leminen A, Tiitnen A, Lehtovirta P, Wahlstrom T, Ylikorkala O. Malignant tumours of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstetricia et Gynecologica Scandinavica 1997;76:177-81.
132. Unkila-Kallio L, Tiitinen A, Wahlstrom T, Lehtovirta P, Leminen A. Reproductive features in women developing ovarian granulosa cell tumour at a fertile age. Human Reproduction 2000;15(3):589-93.
133. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
134. Venn AJ, Healy DL. Fertility drugs and cancer. Reproductive Medicine Review 1997;6(3):185-98.
135. Venn A, Hemminki E, Watson L, Bruinsma F, Healy D. Mortality in a cohort of IVF patients. Human Reproduction 2001;16(12):2691-6.
136. Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Practice & Research Clinical Obstetrics & Gynaecology 2003;17(2):343-67.
137. Vlahos N, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. Annuals of the New York Academy Sciences 2010;1205:214-9.
138. Wakeley KE, Grendys EC. Reproductive technologies and risk of ovarian cancer. Current Opinion of Obstetrics and Gynecology 2000;12:43-7.
139. Whittemore AS. The risk of ovarian cancer after treatment for infertility. New England Journal of Medicine 1994;331(12):805-6.
140. Willemsen W, Kruitwagen R, Bastiaans, Hanselaar T, Rolland R. Ovarian stimulation and granulosa-cell tumour. Lancet 1993;341:986-8.
141. Zreik TG, Ayoub CM, Hannoun A, Karam CJ, Munkarah AR. Fertility drugs and risk of ovarian cancer: dispelling the myth. Current Opinion in Obstetrics and Gynecology 2008;20:313-9.
142. Balasch J, Barri PN. Follicular stimulation and ovarian cancer?. Human Reproduction 1993;8:990-6.
143. Biskind MS, Biskind GS. Development of tumours in the rat ovary after transplantation into the spleen. Proceedings of the Society for Experimental Biology and Medicine 1944;55:176-9.
144. Boivin J, Bunting L, Collins J, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Human Reproduction 2007;22(6):1506-12.
145. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. British Journal of Cancer 1989;60:592-8.
146. Brinton L, Moghiss K, Scoccia B, WesthoffC, Lamb E. Ovulation induction and cancer risk. Fertility and Sterility 2005;83(2):261-74.
147. Brinton LA, Melton LJ, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. American Journal of Epidemiology 1989;129:712-22.
148. Chandra A, Stephen EH. Impaired fecundity in the United States: 1982-1995. Family Planning Perspectives 1998;30:34-42.
149. Duffy JMN, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000099.pub3]
150. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia?. Lancet 1971;2:163.
151. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histological subtype. American Journal of Epidemiology 2010;171:45-53.
152. Greenhall E, Vessey M. The prevalence of subfertility: a review of the current confusion and a report of two new studies. Fertility and Sterility 1990;54:978-83.
153. Healy DL, Trounson AO, Andersen AN. Female infertility: causes and treatment. Lancet 1994;343:1539-44.
154. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. The Richards and Hinda Rosenthal Foundation award lecture. Cancer Research 1988;48:246-53.
155. Higgins JPT, Green S (editors). Cochrane Handbook for Systemic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
156. Homburg R, Ostergard H. Clinical applications of growth hormone for ovarian stimulation. Human Reproduction Update 1995;1:264-75.
157. Karmaus W, Juul S. Infertility and subfecundity in population-based samples from Denmark, Germany, Italy, Poland and Spain. European Journal of Public Health 1999;9:229-35.
158. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta analysis. Obstetrics and Gynecology 2004;103:785-94.
159. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertility and Sterility 2006;85(4):819-26.
160. Meirow D, Schenker JG. The link between female infertility and cancer: epidemiology and possible aetiologies. Human Reproduction 1996;2(1):63-75.
161. Ness RB, Cramer DW, Goodman MT. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. American Journal of Epidemiology 2002;155:217-24.
162. National Institute for Health and Clinical Excellence (NICE). Fertility: assessment and treatment for people with fertility problems (CG156). NICE (guidence.nice.org.uk/cg156) accessed February 2013 2013.
163. Nugent D, Salha O, Balen AH, Rutherford AJ. Ovarian neoplasia and subfertility treatments. British Journal of Obstetrics and Gynaecology 1998;105:584-91.
164. Poretsky L, Cataldo NA, Resenwaks Z, Giudice IC. The insulin-related ovarian regulatory system in health and disease. Endocrine Reviews 1999;20:535-82.
165. Pozlep B, Meden-Vrtovec H. Ovulation induction agents and ovarian cancer. Zdravstveni Vestnik 2001;70:525-9.
166. Rish HA, Marrett LD, Hove GR. Parity, contraception, infertility and the risk of epithelial ovarian cancer. American Journal of Epidemiology 1994;140:585-97.
167. Rish HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal National Cancer Institute Journal 1998;90:1774-86.
168. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology 1987;125:780-90.
169. Rowe PJ, Hargreave TB, Mellows HJ, Comhaire FH. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge University Press, 1993.
170. Schmidt L, Munster K. Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970-1992 a review of concepts, measurements and results. Human Reproduction 1995;10:1407-18.
171. Whittemore AS. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. American Journal of Epidemiology 1992;136(10):1175-83.
172. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. American Journal of Epidemiology 1992;136:1184-203.